2-{4-chloro-1-[3-(1-methyl-piperidin-4-yl)-propyl]-2,3-dihydro-1H-indol-5-yl}-5-fluoro-4-methyl-1H-benzoimidazole | 1161424-71-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-{4-chloro-1-[3-(1-methyl-piperidin-4-yl)-propyl]-2,3-dihydro-1H-indol-5-yl}-5-fluoro-4-methyl-1H-benzoimidazole
• 英文别名: 2-[4-chloro-1-[3-(1-methylpiperidin-4-yl)propyl]-2,3-dihydroindol-5-yl]-5-fluoro-4-methyl-1H-benzimidazole
• CAS: 1161424-71-0
• 化学式: C₂₅H₃₀ClFN₄
• 分子量: 440.991
• InChiKey: GYAUQTABKJDXNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
  申请人：Kindrachuk David E.

  公开号：US20090156613A1

  公开（公告）日：2009-06-18

  Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H 4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H 4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  描述了具有双环杂环芳基取代的咪唑化合物，这些化合物可用作H4受体调节剂。这种化合物可以用于制备药物组合物，用于调节组脊髓H4受体活性以及治疗由H4受体活性介导的疾病状态、紊乱和症状，例如过敏、哮喘、自身免疫疾病和瘙痒症。
• Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders
  申请人：Desmadryl Gilles

  公开号：US20120039913A1

  公开（公告）日：2012-02-16

  The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

  该发明涉及组胺H4受体拮抗剂或组胺H4受体基因表达抑制剂，用于治疗和/或预防前庭障碍。
• SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3130376A1

  公开（公告）日：2017-02-15

  The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

  本发明涉及组胺 H4 受体拮抗剂或组胺 H4 受体基因表达抑制剂，用于治疗和/或预防前庭失调。
• H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS
  申请人：Sensorion

  公开号：EP3378476A1

  公开（公告）日：2018-09-26

  The invention relates to Histamine type 4 receptor (H4R) inhibitors for treating tinnitus.

  本发明涉及用于治疗耳鸣的组胺 4 型受体（H4R）抑制剂。
• Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
  申请人：INSERM (Institut National de la Sante de la Recherche Medicale)

  公开号：US10195195B2

  公开（公告）日：2019-02-05

  The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

  本发明涉及组胺 H4 受体拮抗剂或组胺 H4 受体基因表达抑制剂，用于治疗和/或预防前庭失调。